Lessons learned from the clinical development of oral peptides

被引:41
|
作者
Karsdal, Morten Asser [1 ]
Riis, Bente Juul [1 ]
Mehta, Nozer [2 ]
Stern, William [2 ]
Arbit, Ehud [3 ]
Christiansen, Claus [1 ]
Henriksen, Kim [1 ]
机构
[1] Nord Biosci AS, Herlev, Denmark
[2] Enteris Biopharma Inc, Boonton, NJ USA
[3] Oramed Pharmaceut, Jerusalem, Israel
关键词
bone; calcitonin; cartilage; clinical trial; diabetes; oral formulation; GLUCAGON-LIKE PEPTIDE-1; PARATHYROID-HORMONE RHPTH(1-31)NH2; HEALTHY POSTMENOPAUSAL WOMEN; HUMAN GROWTH-HORMONE; PROOF-OF-CONCEPT; IN-VIVO ACTIVITY; SALMON-CALCITONIN; INTESTINAL-ABSORPTION; BONE TURNOVER; FOOD-INTAKE;
D O I
10.1111/bcp.12557
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The oral delivery of peptides and proteins has been hampered by an array of obstacles. However, several promising novel oral delivery systems have been developed. This paper reviews the most advanced oral formulation technologies, and highlights key lessons and implications from studies undertaken to date with these oral formulations. Special interest is given to oral salmon calcitonin (CT), glucagon-like peptide-1 (GLP-1), insulin, PYY-(3-36), recombinant human parathyroid hormone (rhPTH(1-31)-NH2) and PTH(1-34), by different technologies. The issues addressed include (i) interaction with water, (ii) interaction with food, (iii) diurnal variation, (iv) inter- and intra-subject variability, (v) correlation between efficacy and exposure and (vi) key deliverables of different technologies. These key lessons may aid research in the development of other oral formulations.
引用
收藏
页码:720 / 732
页数:13
相关论文
共 50 条
  • [21] Intelligent Wheelchair: Lessons Learned From Development
    Gomi, Takashi
    TECHNOLOGY AND AGING, 2008, 21 : 173 - 180
  • [22] The development of chemoreflexes - lessons learned from the llama
    Hanson, MA
    JOURNAL OF PHYSIOLOGY-LONDON, 2000, 523 : 20S - 20S
  • [23] Lessons Learned From the Development of an ABOG Subspecialty
    Fenner, Dee E.
    CLINICAL OBSTETRICS AND GYNECOLOGY, 2024, 67 (02): : 326 - 334
  • [24] Some lessons learned from imatinib mesylate clinical development in gastrointestinal stromal tumors
    Casali, PG
    Bertulli, R
    Fumagalli, E
    Coco, P
    Grosso, F
    Stacchiotti, S
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 55 - 58
  • [25] Clinical Pathways Development and Computer Support in the EPR: Lessons learned
    Buerkle, Thomas
    Baur, Thomas
    Hoess, Norbert
    UBIQUITY: TECHNOLOGIES FOR BETTER HEALTH IN AGING SOCIETIES, 2006, 124 : 1025 - +
  • [26] Risk Model Development and Validation in Clinical Oncology: Lessons Learned
    Lyman, Gary H.
    Msaouel, Pavlos
    Kuderer, Nicole M.
    CANCER INVESTIGATION, 2023, 41 (01) : 1 - 11
  • [27] LESSONS LEARNED FROM CLINICAL-TRIALS OF SEPSIS
    OPAL, SM
    JOURNAL OF ENDOTOXIN RESEARCH, 1995, 2 (03): : 221 - 226
  • [28] The lessons learned from randomized clinical trials of GERD
    Pace, F.
    Sonnenberg, A.
    Porro, G. Bianchi
    DIGESTIVE AND LIVER DISEASE, 2007, 39 (11) : 993 - 1000
  • [29] Lessons learned from clinical nurse specialist longevity
    Boyle, DM
    JOURNAL OF ADVANCED NURSING, 1997, 26 (06) : 1168 - 1174
  • [30] Lessons Learned from Radiation Oncology Clinical Trials
    Liu, Fei-Fei
    Okunieff, Paul
    Bernhard, Eric J.
    Stone, Helen B.
    Yoo, Stephen
    Coleman, C. Norman
    Vikram, Bhadrasain
    Brown, Martin
    Buatti, John
    Guha, Chandan
    CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6089 - 6100